MY161095A - Indole compound and pharmaceutical use thereof - Google Patents
Indole compound and pharmaceutical use thereofInfo
- Publication number
- MY161095A MY161095A MYPI2012002292A MYPI2012002292A MY161095A MY 161095 A MY161095 A MY 161095A MY PI2012002292 A MYPI2012002292 A MY PI2012002292A MY PI2012002292 A MYPI2012002292 A MY PI2012002292A MY 161095 A MY161095 A MY 161095A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceutical use
- indole compound
- diseases
- prophylaxis
- solvate
- Prior art date
Links
- -1 Indole compound Chemical class 0.000 title 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009268040 | 2009-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY161095A true MY161095A (en) | 2017-04-14 |
Family
ID=44066507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012002292A MY161095A (en) | 2009-11-25 | 2010-11-25 | Indole compound and pharmaceutical use thereof |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US8299070B2 (enExample) |
| EP (3) | EP3059234A1 (enExample) |
| JP (6) | JP5734628B2 (enExample) |
| KR (1) | KR101766502B1 (enExample) |
| CN (1) | CN102712624B (enExample) |
| AR (1) | AR079164A1 (enExample) |
| AU (1) | AU2010323579C1 (enExample) |
| BR (1) | BR112012012529B1 (enExample) |
| CA (1) | CA2781660C (enExample) |
| CL (1) | CL2012001328A1 (enExample) |
| CO (1) | CO6541645A2 (enExample) |
| CY (1) | CY1117559T1 (enExample) |
| DK (1) | DK2505586T3 (enExample) |
| ES (1) | ES2572935T3 (enExample) |
| HR (1) | HRP20160579T1 (enExample) |
| HU (1) | HUE028016T2 (enExample) |
| IL (1) | IL220009A (enExample) |
| ME (1) | ME02447B (enExample) |
| MX (1) | MX2012006017A (enExample) |
| MY (1) | MY161095A (enExample) |
| NZ (1) | NZ600840A (enExample) |
| PE (1) | PE20121358A1 (enExample) |
| PH (1) | PH12012501021A1 (enExample) |
| PL (1) | PL2505586T3 (enExample) |
| PT (1) | PT2505586E (enExample) |
| RS (1) | RS54910B1 (enExample) |
| RU (1) | RU2556216C2 (enExample) |
| SI (1) | SI2505586T1 (enExample) |
| SM (1) | SMT201600258B (enExample) |
| TW (1) | TWI491591B (enExample) |
| WO (1) | WO2011065402A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
| NZ736048A (en) | 2010-06-03 | 2019-09-27 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| KR20180088926A (ko) | 2012-07-24 | 2018-08-07 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| KR20150080592A (ko) | 2012-11-02 | 2015-07-09 | 파마시클릭스, 인코포레이티드 | Tec 패밀리 키나제 억제제 애쥬번트 요법 |
| CN103804364A (zh) * | 2012-11-06 | 2014-05-21 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| CN103804361A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800337A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103804291A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800328A (zh) * | 2012-11-07 | 2014-05-21 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| CN103800340A (zh) * | 2012-11-09 | 2014-05-21 | 韩冰 | 一类治疗青光眼的化合物及其用途 |
| CN103804351A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804363A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804272A (zh) * | 2012-11-14 | 2014-05-21 | 韩冰 | 一类具有神经保护作用的化合物及其用途 |
| CN103804302A (zh) * | 2012-11-14 | 2014-05-21 | 杨育新 | 一类治疗创伤性脑损伤疾病的化合物及其用途 |
| CN104628657A (zh) * | 2013-11-06 | 2015-05-20 | 韩冰 | 一类治疗缺血性脑损伤的化合物及其用途 |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| AR099936A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| WO2016002918A1 (ja) * | 2014-07-04 | 2016-01-07 | 日本たばこ産業株式会社 | インドール化合物の製造方法 |
| WO2016010108A1 (ja) * | 2014-07-18 | 2016-01-21 | 塩野義製薬株式会社 | 含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| CN104356086A (zh) * | 2014-11-28 | 2015-02-18 | 湖南科技大学 | 一种适于工业生产3-吗啉酮的制备方法 |
| EP3804727B1 (en) * | 2018-05-25 | 2023-10-11 | Japan Tobacco Inc. | Indol-containing compound for use in the treatment of the nephrotic syndrome |
| WO2019225740A1 (ja) | 2018-05-25 | 2019-11-28 | 日本たばこ産業株式会社 | インドール化合物を含む多発性硬化症の治療又は予防剤 |
| ES2983998T3 (es) * | 2018-05-25 | 2024-10-28 | Japan Tobacco Inc | Compuesto de indol para tratar la cistitis intersticial |
| AU2020405536B2 (en) | 2019-12-20 | 2023-09-07 | Pfizer Inc. | Benzimidazole derivatives |
| KR102270026B1 (ko) * | 2020-01-31 | 2021-06-28 | 현대약품 주식회사 | (3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법 |
| CA3205020A1 (en) * | 2020-12-15 | 2022-06-23 | Pfizer Inc. | Benzimidazole derivatives and their use as inhibitors of itk for the treatment of skin disease |
| EP4263538A1 (en) * | 2020-12-15 | 2023-10-25 | Pfizer Inc. | Pyrido[2,3-d]imidazole derivatives and their use as inhibitors of itk for the teatment of skin disease |
| WO2022235698A1 (en) * | 2021-05-03 | 2022-11-10 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| JP2024517831A (ja) * | 2021-05-03 | 2024-04-23 | ニューリックス セラピューティクス，インコーポレイテッド | Ｉｔｋを阻害又は分解するための化合物、それを含む組成物、それらの作製方法及びそれらの使用方法 |
| TW202315618A (zh) * | 2021-06-11 | 2023-04-16 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物 |
| US20250002489A1 (en) * | 2021-10-19 | 2025-01-02 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading itk via ubiquitin proteosome pathway |
| WO2024213082A1 (en) * | 2023-04-13 | 2024-10-17 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolone derivatives, compositions and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US953411A (en) * | 1908-09-02 | 1910-03-29 | Erastus De Moulin | Trick weight-lifting machine. |
| EP1441725A1 (en) * | 2001-10-26 | 2004-08-04 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| WO2003057696A1 (en) * | 2002-01-07 | 2003-07-17 | Eisai Co. Ltd. | Deazapurines and uses thereof |
| JP2003231687A (ja) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| FR2854159B1 (fr) * | 2003-04-25 | 2008-01-11 | Aventis Pharma Sa | Nouveaux derives de l'indole, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de kdr |
| US20050032869A1 (en) * | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| KR20060069490A (ko) * | 2003-09-08 | 2006-06-21 | 아벤티스 파마슈티칼스 인크. | 티에노피라졸 |
| WO2006112479A1 (ja) * | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | 含窒素複素環化合物 |
| WO2007076228A2 (en) | 2005-12-20 | 2007-07-05 | Boehringer Ingelheim International Gmbh | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders |
| GB0602178D0 (en) * | 2006-02-03 | 2006-03-15 | Merck Sharp & Dohme | Therapeutic treatment |
| EP2001480A4 (en) * | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| US8604031B2 (en) * | 2006-05-18 | 2013-12-10 | Mannkind Corporation | Intracellular kinase inhibitors |
| EP2108642A1 (en) * | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
| US8362066B2 (en) | 2006-11-17 | 2013-01-29 | Treventis Corporation | Compounds and methods for treating protein folding disorders |
| UA99459C2 (en) | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
| JP2009268040A (ja) | 2008-04-23 | 2009-11-12 | Teruhiko Daiho | ループアンテナ装置 |
| US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
-
2010
- 2010-11-24 US US12/954,438 patent/US8299070B2/en active Active
- 2010-11-25 ES ES10833248.7T patent/ES2572935T3/es active Active
- 2010-11-25 EP EP16158053.5A patent/EP3059234A1/en not_active Withdrawn
- 2010-11-25 PT PT108332487T patent/PT2505586E/pt unknown
- 2010-11-25 DK DK10833248.7T patent/DK2505586T3/en active
- 2010-11-25 AU AU2010323579A patent/AU2010323579C1/en active Active
- 2010-11-25 BR BR112012012529-0A patent/BR112012012529B1/pt active IP Right Grant
- 2010-11-25 SI SI201031188A patent/SI2505586T1/sl unknown
- 2010-11-25 KR KR1020127016311A patent/KR101766502B1/ko active Active
- 2010-11-25 MY MYPI2012002292A patent/MY161095A/en unknown
- 2010-11-25 CA CA2781660A patent/CA2781660C/en active Active
- 2010-11-25 PE PE2012000713A patent/PE20121358A1/es active IP Right Grant
- 2010-11-25 PH PH1/2012/501021A patent/PH12012501021A1/en unknown
- 2010-11-25 CN CN201080062299.3A patent/CN102712624B/zh active Active
- 2010-11-25 EP EP20189306.2A patent/EP3766877A1/en not_active Withdrawn
- 2010-11-25 TW TW099140715A patent/TWI491591B/zh active
- 2010-11-25 HR HRP20160579TT patent/HRP20160579T1/hr unknown
- 2010-11-25 MX MX2012006017A patent/MX2012006017A/es active IP Right Grant
- 2010-11-25 ME MEP-2016-107A patent/ME02447B/me unknown
- 2010-11-25 RU RU2012126129/04A patent/RU2556216C2/ru active
- 2010-11-25 JP JP2010262058A patent/JP5734628B2/ja active Active
- 2010-11-25 AR ARP100104362A patent/AR079164A1/es active IP Right Grant
- 2010-11-25 NZ NZ600840A patent/NZ600840A/en unknown
- 2010-11-25 PL PL10833248.7T patent/PL2505586T3/pl unknown
- 2010-11-25 WO PCT/JP2010/070988 patent/WO2011065402A1/ja not_active Ceased
- 2010-11-25 HU HUE10833248A patent/HUE028016T2/en unknown
- 2010-11-25 EP EP10833248.7A patent/EP2505586B1/en active Active
- 2010-11-25 RS RS20160385A patent/RS54910B1/sr unknown
-
2012
- 2012-05-23 CL CL2012001328A patent/CL2012001328A1/es unknown
- 2012-05-24 IL IL220009A patent/IL220009A/en active IP Right Grant
- 2012-06-22 CO CO12105036A patent/CO6541645A2/es active IP Right Grant
- 2012-09-26 US US13/627,047 patent/US20130116240A1/en not_active Abandoned
-
2015
- 2015-04-15 JP JP2015083457A patent/JP2015172051A/ja not_active Ceased
-
2016
- 2016-05-26 CY CY20161100462T patent/CY1117559T1/el unknown
- 2016-08-03 SM SM201600258T patent/SMT201600258B/it unknown
- 2016-10-20 JP JP2016205949A patent/JP2017039761A/ja not_active Ceased
- 2016-10-28 US US15/337,583 patent/US20170267662A1/en not_active Abandoned
-
2018
- 2018-01-12 US US15/869,250 patent/US20180362506A1/en not_active Abandoned
- 2018-06-13 JP JP2018112445A patent/JP2018158935A/ja active Pending
-
2019
- 2019-09-19 US US16/575,724 patent/US20200255408A1/en not_active Abandoned
-
2020
- 2020-02-04 JP JP2020017065A patent/JP2020079276A/ja not_active Ceased
- 2020-09-23 US US17/029,642 patent/US20210284627A1/en not_active Abandoned
-
2021
- 2021-03-03 JP JP2021033138A patent/JP2021091718A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12012501021A1 (en) | Indole compound and pharmaceutical use thereof | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| HK1216176A1 (zh) | 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 | |
| MY163495A (en) | Nitrogen-containing spiro-ring compound and medicinal use of same | |
| AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
| TW201129565A (en) | Tricyclic heterocyclic compounds, compositions and methods of use thereof | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| MX360697B (es) | Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| MX2012006491A (es) | Derivados de oxazina. | |
| MX360634B (es) | Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos. | |
| IN2012DN01855A (enExample) | ||
| PT2432760E (pt) | Derivados de espiro [2,4] heptano ligados em ponte como agonistas do receptor fprl2 e/ou receptor alx | |
| MY183974A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| MY162397A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| MX2010008460A (es) | Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular. | |
| IN2012DN03182A (enExample) | ||
| MY172422A (en) | Pyrazole compound and pharmaceutical use thereof | |
| MX357676B (es) | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado. | |
| MX2013006418A (es) | Derivados de oxazolil-metileter como agonistas del receptor de alx. | |
| MX2013006420A (es) | Derivados de aminotriazol hidrolixado como agonistas del receptor de alx. | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| MY173491A (en) | Therapeutic or prophylactic agent for biliary tract diseases | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| WO2012074869A8 (en) | Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture | |
| MX2009006325A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. |